Univ. Bordeaux ISPED, Inserm Bordeaux Population Health Research Center UMR 1219, Inria BSO, team SISTM, F-33000 Bordeaux, France.
Bordeaux Population Health Research Center, Inserm U1219, Université de Bordeaux, 146 rue Léo Saignat, 33076, F-33000, Bordeaux, France; Agence régionale de santé Nouvelle-Aquitaine, 103 bis rue de Belleville, F-33000 Bordeaux, France.
J Clin Virol. 2021 Aug;141:104878. doi: 10.1016/j.jcv.2021.104878. Epub 2021 Jun 5.
There is a lack of data evaluating performance of antigenic test (AT) for SARS-CoV-2 diagnosis (Ag-RDT) in clinical practice, especially in asymptomatic subjects. The main objective of this study was to evaluate the diagnostic performance of AT compared to Reverse Transcription Polymerase Chain Reaction (RT-PCR) for SARS-CoV-2 diagnosis.
StudyCov is a monocentric cross-sectional study. A SARS-CoV-2 screening facility was set up in the Bordeaux University health campus from October 28th to November 20th 2020. Students willing to have a RT-PCR test (ARGENE SARS-CoV-2 R-GENE, BioMérieux, France) for SARS-CoV-2 diagnosis were also offered the Abbott Panbio™ SARS-CoV-2 antigenic rapid test. All participants attending the screening facility with an AT in addition to RT-PCR and having signed an informed consent were included in the study. The main objective was to assess performance of AT as compared with RT-PCR in the recruited population. Secondary objectives dealt with the analysis of the main objective stratified by current symptoms and risk exposure. A sensitivity analysis with different RT-PCR cycle thresholds was included.
RT-PCR and AT results were available for 692 subjects. Overall sensitivity and specificity of AT tests were respectively 63.5% (95% confidence interval (CI): 49.0 - 76.4) and 100% (95% CI: 99.4 - 100). In the asymptomatic sub-group, they were respectively 35.0% (95% CI: 15.4% - 59.2%) and 100% (95% CI: 99.3 - 100).
This study shows the poor sensitivity of AT in asymptomatic subjects, specificity being however excellent. The performance results fall below the World Health Organization recommendation of 80% sensitivity and question using AT in general population, especially when asymptomatic.
目前缺乏评估抗原检测(AT)用于 SARS-CoV-2 诊断(Ag-RDT)的临床性能的数据,尤其是在无症状人群中。本研究的主要目的是评估 AT 与逆转录聚合酶链反应(RT-PCR)相比用于 SARS-CoV-2 诊断的诊断性能。
StudyCov 是一项单中心横断面研究。2020 年 10 月 28 日至 11 月 20 日,在波尔多大学健康校园内建立了一个 SARS-CoV-2 筛查设施。愿意接受用于 SARS-CoV-2 诊断的 RT-PCR 测试(ARGENE SARS-CoV-2 R-GENE,法国生物梅里埃公司)的学生也可以接受 Abbott Panbio™ SARS-CoV-2 抗原快速检测。所有参加筛查设施并进行 RT-PCR 检测且签署知情同意书的参与者均被纳入研究。主要目标是评估 AT 在招募人群中的表现与 RT-PCR 的比较。次要目标涉及按当前症状和风险暴露分层对主要目标的分析。还包括了不同 RT-PCR 循环阈值的敏感性分析。
RT-PCR 和 AT 结果可用于 692 名受试者。AT 检测的总体敏感性和特异性分别为 63.5%(95%置信区间(CI):49.0-76.4)和 100%(95%CI:99.4-100)。在无症状亚组中,它们分别为 35.0%(95%CI:15.4%-59.2%)和 100%(95%CI:99.3%-100)。
本研究表明 AT 在无症状人群中的敏感性较差,但特异性极佳。性能结果低于世界卫生组织推荐的 80%敏感性,这对一般人群中使用 AT 提出了质疑,尤其是在无症状人群中。